Tags : JT

PharmaShots Weekly Snapshot (January 13-17, 2020)

1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated Heart 2. Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment Published: Jan 16, 2020 | Tags: Charles River, Collaborates, Fios Genomics, […]Read More

JT Signs an Exclusive License Agreement with Dermavant to Develop

Shots: Dermavant to receive $60M up front, up to $53M as development milestones and royalties on sales of the tapinarof in psoriasis and AD. JT and its subsidiary, Torii Pharmaceutical to get rights to develop & commercialize tapinarof for psoriasis and AD in Japan Additionally, JT has signed an exclusive license agreement with Torii to […]Read More